Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
urogenital diseases | D000091642 |
Brand Name | Status | Last Update |
---|---|---|
nubeqa | New Drug Application | 2023-10-13 |
Expiration | Code | ||
---|---|---|---|
DAROLUTAMIDE, NUBEQA, BAYER HEALTHCARE | |||
2025-08-05 | I-900 | ||
2024-07-30 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 7 | 18 | 13 | 2 | 10 | 47 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 3 | 3 | 1 | 4 | 11 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 2 | 3 | — | 3 | 8 |
Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
Lymphatic metastasis | D008207 | EFO_1001364 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Cerebrovascular circulation | D002560 | — | — | 1 | — | — | — | — | 1 |
Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Male breast neoplasms | D018567 | — | — | 1 | — | — | — | — | 1 |
Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Liver failure | D017093 | — | K72.9 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Darolutamide |
INN | darolutamide |
Description | Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.
|
Classification | Small molecule |
Drug class | non-steroid antiandrogens |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1 |
PDB | — |
CAS-ID | 1297538-32-9 |
RxCUI | — |
ChEMBL ID | CHEMBL4297185 |
ChEBI ID | — |
PubChem CID | 67171867 |
DrugBank | DB12941 |
UNII ID | X05U0N2RCO (ChemIDplus, GSRS) |